

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

RECEIVED
JUN 13 2005
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Atty. M# Client Ref.
Dkt. No. 051501-0305443

Applicant: Michael Croft, et al.

Appln. No.: 10/661,358

Filing Date: September 11, 2003

Date: June 9, 2005

Page 1 Of 1

Examiner: Not yet assigned Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
JO	AR 5,759,546	06/1998	Weinberg, et al.	424	179.1	
	BR 6,312,700	11/2001	Weinberg	424	278.1	
	CR 6,566,082	05/2003	Weinberg, et al.	435	7.24	
	DR US 2002/0054873 A1	05/2002	Weinberg	424	141.1	

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
ER WO 95/21251	08/1995	WO	Weinberg, et al.	Enclosed	No
FR WO 99/42585	08/1999	WO	Weinberg	Enclose	No

OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

GR	Evans, Dean E., et al., Engagement of OX40 Enhances Antigen-Specific CD4 ⁺ T Cell Mobilization/Memory Development and Humoral Immunity: Comparison of αOX-40 with αCTLA-4, <i>J. of Immunology</i> , 2001, 167:6804-6811.				
HR	Gramaglia, Irene, et al., Ox-40 Ligand: A Potent Costimulatory Molecule for Sustaining Primary CD4 T Cell Responses, <i>J. of Immunology</i> , 1998, 161:6510-6517.				
IR	Gramaglia, Irene, et al., The OX40 Costimulatory Receptor Determines the Development of CD4 Memory by Regulating Primary Clonal Expansion, <i>J. of Immunology</i> , 2000, 165:3043-3050.				
JR	Kjaergaard, Jorgen, et al., Augmentation Versus Inhibition: Effects of Conjunctonal OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor, <i>J. of Immunology</i> , 2001, 167: 6669-6677.				
KR	Maxwell, Joseph R., et al., Danger and OX40 Receptor Signaling Synergize to Enhance Memory T Cell Survival by Inhibiting Peripheral Deletion, <i>J. of Immunology</i> , 2000, 164:107-112.				
LR	Pan, Ping-Ying, OX40 Ligation Enhances Primary and Memory Cytotoxic T Lymphocyte Responses in an Immunotherapy for Hepatic Colon Metastases, <i>Molecular Therapy</i> , 6(4):528-536 (2002)				
JO MR	Weatherill, Amy R., et al., OX40 Ligation Enhances Cell Cycle Turnover of Ag-Activated CD4 T Cell in Vivo, <i>Cellular Immunology</i> , 209, 63-75 (2001)				

Ilia Anspenski 9/20/05

IO	NR	Weinberg, Andrew D., et al., Blocking OX-40/OX-40 Ligand Interaction In Vitro and In Vivo Leads to Decreased T Cell Function and Amelioration of Experimental Allergic Encephalomyelitis, <i>J. of Immunology</i> , 1999, 162: 1818-1826.				
IO	OR	Weinberg, Andrew D., Ox40: Targeted Immunotherapy-Implications for Tempering Autoimmunity and enhancing Vaccines, <i>TRENDS in Immunology</i> , 20(2):102-109 (February 2002)				
Examiner		Dion Cherpenski		Date Considered: 9/20/05		
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>						